Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effect of Nano-Hyaluronic Acid in Intrabony Defects Treated With Minimally Invasive Non-Surgical Technique

15. mai 2026 oppdatert av: Mustafa Hussein Alshebli, Cairo University

Clinical Evaluation of Nano-Hyaluronic Acid as an Adjunctive to Minimally Invasive Non-Surgical Technique in the Treatment of Deep Intrabony Defects: Randomized Controlled Clinical Trial

This randomized controlled clinical trial aims to evaluate the effectiveness of using nano-hyaluronic acid (nano-HyA) gel alongside a minimally invasive non-surgical technique (MINST) to treat deep intrabony defects in patients with Stage II and III periodontitis. While MINST is a proven method for cleaning deep periodontal pockets without the need for traditional surgery , the addition of nano-HyA may further enhance soft tissue healing, reduce inflammation, and promote regeneration. Participants in the study will be randomly assigned to one of two groups. The test group will receive the MINST procedure combined with the application of nano-HyA gel into the periodontal pocket, while the control group will receive the MINST procedure alone. The primary goal of the study is to measure the decrease in probing pocket depth over a 6-month follow-up period to determine if the adjunctive use of nano-HyA provides superior clinical and radiographic outcomes compared to non-surgical treatment alone

Studieoversikt

Status

Aktiv, ikke rekrutterende

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Faktiske)

28

Fase

  • Fase 2
  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Cairo Governorate
      • Cairo, Cairo Governorate, Egypt
        • Faculty of Dentistry, Cairo University

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  1. Males and females aged ≥ 18 years.
  2. Patients with a diagnosis of periodontitis (stage II or III).
  3. At least one tooth with ≥5 mm PPD and CAL and evidence of radiographic bone loss.
  4. Presenting with at least 1 intrabony defect, with a radiographic intra-bony component ≥3 mm.

Exclusion Criteria:

  1. Patients with systemic diseases.
  2. Pregnant or lactating females.
  3. Tobacco smokers (≥ 10 cigarettes per day).
  4. Multi-rooted teeth with class II and class III furcation defects.
  5. Third molars.
  6. Teeth with grade III mobility.
  7. Peri-apical pathology and acute abscess.
  8. Non-surgical or surgical periodontal treatment in the past 12 months.
  9. Prolonged treatment with antibiotics or anti-inflammatory agents within 6 months before periodontal therapy.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: MINST alone
Participants receive the minimally invasive non-surgical technique (MINST) alone without adjunctive treatment
Subgingival debridement using thin ultrasonic tips and additional instrumentation with Gracey mini-curettes, deliberately avoiding subgingival rinsing to support blood clot stabilization
Eksperimentell: MINST + nano-hyaluronic acid
Participants receive MINST combined with adjunctive nano-hyaluronic acid
Subgingival debridement using thin ultrasonic tips and additional instrumentation with Gracey mini-curettes, deliberately avoiding subgingival rinsing to support blood clot stabilization
Pockets associated with intrabony defects are filled with nano-HyA paste immediately after subgingival debridement

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Pocket Depth (PD)
Tidsramme: "From enrollment to the end of treatment at 24 weeks"
Measured in millimeters (mm) from the gingival margin to the bottom of the gingival sulcus using a UNC-15 periodontal probe. Each tooth is probed at 6 sites with a light force not exceeding 25 grams.
"From enrollment to the end of treatment at 24 weeks"

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Full-Mouth Plaque Score (FMPS)
Tidsramme: From enrollment to the end of treatment at 24 weeks
Assessed as the percentage of sites with plaque.
From enrollment to the end of treatment at 24 weeks
Full-Mouth Bleeding Score (FMBS)
Tidsramme: From enrollment to the end of treatment at 24 weeks
Assessed as the percentage of sites with bleeding upon probing.
From enrollment to the end of treatment at 24 weeks
Clinical Attachment Level (CAL)
Tidsramme: From enrollment to the end of treatment at 24 weeks
Measured in millimeters (mm) from the cemento-enamel junction to the bottom of the pocket.
From enrollment to the end of treatment at 24 weeks
Gingival Recession (GR)
Tidsramme: From enrollment to the end of treatment at 24 weeks
Measured in millimeters (mm) from the cemento-enamel junction to the gingival margin.
From enrollment to the end of treatment at 24 weeks
Radiographic Defect Angle (RDA)
Tidsramme: From enrollment to the end of treatment at 24 weeks
Measured in degrees (°).
From enrollment to the end of treatment at 24 weeks
Patient Satisfaction
Tidsramme: From enrollment to the end of treatment at 24 weeks
Assessed via a Likert-scale questionnaire. The scale ranges from 1 to 5, where 1 indicates "Very Dissatisfied" and 5 indicates "Very Satisfied". Higher scores represent a better outcome.
From enrollment to the end of treatment at 24 weeks
Cost Effectiveness
Tidsramme: From enrollment to the end of treatment at 24 weeks
Evaluated through a health economic analysis, measured as currency per unit effect.
From enrollment to the end of treatment at 24 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

15. juli 2025

Primær fullføring (Antatt)

1. august 2026

Studiet fullført (Antatt)

29. august 2026

Datoer for studieregistrering

Først innsendt

11. mai 2026

Først innsendt som oppfylte QC-kriteriene

15. mai 2026

Først lagt ut (Faktiske)

19. mai 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

19. mai 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

15. mai 2026

Sist bekreftet

1. mai 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • PER 3-3 -2

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .